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Conclusions. CsA treatment was associated with increasedExpression of multidrug resistance P-glycoprotein in kidney
P-gp expression in parenchymal cells of kidney transplants withallografts from cyclosporine A-treated patients.
ATN, acute or chronic transplant rejection, but P-gp was notBackground. The multidrug resistance (MDR) gene product
increased in patients with CsA nephrotoxicity. This indicatesP-glycoprotein (P-gp) is a transmembrane efflux pump for hy-
that CsA induces its own detoxification by P-gp and that inade-drophobic, potentially toxic compounds, including the immuno-
suppressant cyclosporine A (CsA). We have previously shown quate up-regulation of P-gp in renal parenchymal cells contrib-
that CsA increases P-gp expression in proximal tubule and utes to CsA nephrotoxicity. Increased expression of P-gp in
endothelial cells in vitro. The aim of the present study was to infiltrating leukocytes correlated with the severity of allograft
investigate the in vivo relevance of these observations in renal rejection, suggesting that P-gp may decrease the immunosup-
allograft biopsies from CsA-treated patients. pressive efficacy of CsA. Thus, individual differences in the
Methods. P-gp expression was determined by immunohisto- P-gp induction response of CsA-exposed renal parenchymal
chemistry of paraffin sections using two different monoclonal cells and/or infiltrating leukocytes may predispose to either
antibodies (UIC2 and MRK16). Biopsies were taken from CsA- CsA nephrotoxicity or rejection, respectively.
treated renal transplant patients with different histopathological
diagnoses (N  79) and were compared with biopsies from
normal human kidneys (N  13) or with allograft biopsies from
New options of immunosuppressive therapy have im-patients under a CsA-free immunosuppression (N 15). More-
over, biopsies from 10 donor kidneys before implantation and proved short-term allograft survival [1]. In contrast, the
during rejection episodes (“zero biopsies”) were investigated. reduced transplantation half-life with a five-year allo-
Results. P-gp expression in biopsies with acute tubular ne- graft survival of about 50% is still a major problem [2, 3].crosis (ATN; N  10) after CsA treatment was significantly
Several studies have shown that long-term allograft losshigher in arterial endothelia, proximal tubules, and epithelial
is caused by immunologic and nonimmunologic factors.cells of Bowman’s capsule (BC), whereas P-gp was sparsely
induced in CsA nephrotoxicity (N  19) compared with con- Recurrent rejection episodes and cyclosporine A (CsA)
trols. Acute cellular (N  30) and vascular rejection (N  toxicity are two major reasons for long-term allograft
10) or chronic allograft nephropathy (N  10) after CsA was
failure [4, 5].associated with strong P-gp expression in infiltrating leukocytes
From an immunologic point of view, acute rejectionand increased P-gp expression in arterial endothelia, proximal
tubules, and BC. In contrast, biopsies of patients treated with episodes are initiated when T-cell receptors are activated
a CsA-free immunosuppression regimen did not show increases by a foreign antigen and proliferation of activated lym-
in P-gp expression compared with controls. Zero biopsies showed phocytes is increased combined with an increased produc-a weak, homogeneous, nonpolarized expression of P-gp in tu-
tion of the lymphoproliferative cytokine interleukin-2bules and an increased expression of P-gp after CsA therapy
(IL-2) [6–8]. The immunosuppressive drug CsA, a mac-in the brush border, arterial endothelia, and BC.
rolide antibiotic, inhibits the key enzyme calcineurin
phosphatase, which prevents dephosphorylation of the1 Present address: Department of Nephrology and Rheumatology,
Georg-August-University Go¨ttingen, 37075 Go¨ttingen, Germany. nuclear factor of activated T cells (NF-AT) required for
transcription of early T-cell activation genes, such as IL-2
Key words: nephrotoxicity, acute tubular necrosis, immunosuppres-
[9, 10]. Thus, the main immunosuppressive effect of CsAsion, allograft rejection, chronic allograft nephropathy, renal biopsy,
transplantation, cytokines. is the inhibition of T-cell proliferation by a reduction of
IL-2 secretion. A major side effect of CsA therapy is
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zyme system [12], and (2) efflux of CsA via membrane METHODS
transporters for xenobiotics, including the members of the Materials
adenosine 5-triphosphate (ATP)-binding cassette trans- The following reagents were obtained from the listed
porter superfamily, multispecific organic anion transporter sources and used at the concentrations indicated. Mouse
(MRP2) [13], and the multidrug resistance (MDR) gene monoclonal antibodies (mAbs) MRK16 (Biozol, Mu-
product P-glycoprotein (P-gp) [14]. nich, Germany), UIC2 (Immunotech, Marseille, France),
P-glycoprotein is a transmembrane efflux pump that is or C219 (Alexis Deutschland, Gru¨nberg, Germany) were
expressed in the apical plasma membrane of many excre- used for detection of P-gp. Secondary antibodies [horse-
tory epithelia, such as bile canaliculi, intestine, proximal radish peroxidase (HRP)-conjugated rabbit anti-mouse
tubules (PTs), and endothelia of the blood–brain barrier, and the peroxidase substrate 3-amino-9-ethyl-carbazol
(AEC)] were purchased from Dako Diagnostika (Ham-as well as in the cell membrane of leukocytes [15–19].
burg, Germany), and peroxidase (POD)-conjugated goatThe physiological function of P-gp is not really under-
anti-rabbit was purchased from Dianova (Hamburg, Ger-stood, but it has been associated with the extrusion of
many). HRP-conjugated sheep anti-mouse and enhancedtoxic hydrophobic xenobiotics and drugs such as the im-
chemiluminescence reagents were purchased from Amer-munosuppressants CsA and tacrolimus (FK506), and
sham-Buchler (Braunschweig, Germany). Polyvinyldenealso of cytokines, especially IL-2, out of cells [14, 17].
difluoride (PVDF) membranes were from NEN-DupontIn previous in vitro experiments, we showed that incuba-
(Bad Homburg, Germany). Stock solutions of CsA (Sigma,tion of tubular and endothelial cell lines with CsA in-
Deisenhofen, Germany) were made in dimethyl sulfox-creased P-gp expression and function, suggesting that
ide (DMSO). TNF- was purchased from R&D Systemsup-regulation of P-gp represents a protective mechanism
(Munich, Germany) and was dissolved in distilled water.
of cells against CsA toxicity [20]. Consequently, this im-
All other substances were from commercial sources and
plies that drug-induced or otherwise induced up-regula- of analytical grade.
tion of P-gp plays a pivotal role for the immunosuppressive
efficacy of CsA in lymphocytes and CsA nephrotoxicity Tissue specimens
in renal parenchymal cells. Tissue specimens taken for diagnostic purposes were
Both acute rejection episodes and CsA nephrotoxicity obtained from patients of the Department of Internal
are diagnosed by renal biopsies. The rejection process Medicine IV (University of Erlangen-Nu¨rnberg) and the
is characterized by a lymphocytic infiltration of tubules Department of Nephrology (University of Frankfurt/
and/or vessels [21]. On the other hand, acute CsA neph- Main). Allograft biopsies of CsA-treated renal trans-
rotoxicity appears as tubular vacuolization and, if the plant recipients with clinical diagnostic and histologic
process becomes chronic, results in interstitial fibrosis criteria of ATN (N  10), acute cellular (N  30) or
vascular rejection (N  10), acute (N  8) and chronicand a characteristic media hyalinosis of arterioles, the
(N 11) CsA-associated nephrotoxicity [11], and chronicCsA-associated arteriolopathy [11].
allograft nephropathy (N  10) were investigated. Biop-The present study was performed to investigate P-gp
sies with cellular rejection were classified according toexpression in renal parenchymal cells and infiltrating
the Banff criteria [21] as Banff grades I and IIA andlymphocytes of renal allograft biopsies from CsA-treated
biopsies with vascular rejection as Banff grades IIBpatients with acute tubular necrosis (ATN), acute cellu-
or III. Allograft biopsies from kidney transplant patientslar and/or vascular rejection, chronic allograft nephropa-
with CsA-free immunosuppression (MMF and azathio-thy, and acute and chronic CsA nephrotoxicity. Biopsies
prine, N  15) and biopsies (N  13) from patientsafter CsA treatment were compared with biopsies from
suspected of having kidney diseases, which did not shownormal human kidneys or from kidney transplant pa-
any histopathological signs of kidney disease, were con-
tients treated with CsA-free immunosuppressive regi-
sidered controls for the CsA treatment biopsies. The
mens [such as mycophenolate mofetil (MMF) and azathi- control patients had low-grade proteinuria, microhema-
oprine] used as controls. Furthermore, we examined the turia, and a rise in serum creatinine without any obvious
time course of P-gp expression in renal parenchymal reason. These pathological laboratory parameters were
cells before (zero biopsy of cadaveric donor organs taken not caused by structural damage to the kidneys. Biopsies
after cold ischemia) and after CsA therapy. The biopsy of 10 cadaveric donor kidneys were taken before implan-
data were complemented by in vitro studies of P-gp ex- tation (“zero biopsies”) and were compared with subse-
pression in peripheral blood mononuclear cells (PBMCs) quent biopsies taken for diagnostic reasons because of
of normal donors treated with therapeutically relevant deterioration of graft function. Tissue specimens were
concentrations of CsA or with the inflammatory cytokine fixed in 4% paraformaldehyde and were used for immuno-
histochemical detection, as described later in this article.tumor necrosis factor- (TNF-).
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Table 1. Demographic data of patients used as normal controls, transplant recipients with CsA or CsA-free immunosuppression
Chronic Acute/chronic
Normal CsA Cellular Vascular allograft allograft
Diagnosis kidneys ATN nephrotoxicity rejection rejection nephropathy nephropathy
CsA treatment No Yes Yes Yes Yes Yes No
N 13 10 19 30 10 10 15
Age of patients years 40.515.7a 46.821.2 44.913.0 41.010.9 47.310.1 43.110.6 49.310.8
Age of donors years — 42.36.2 54.712.9 47.715.3 41.514.5 45.711.4 44.311.9
Male:female 7:6 7:3 10:9 21:9 5:5 5:5 9:6
Preformed HLA antibodies
(5%) — 2/10 2/19 4/30 1/10 1/10 1/15
Number of HLA mismatches — 2.752.19 1.01.0 1.811.03 1.890.93 2.80.8 2.11.1
Median time after
transplantation days — 9 443 57 127 1781 2503
Serum creatinine at time
of biopsy mg/dL — 8.31.8 2.71.0 2.81.5 4.11.8 3.11.1 3.11.0
Serum creatinine 1 year
after biopsy mg/dL — 2.10.2 2.50.6 1.90.8 3.41.9 —b —c
Abbreviations are: CsA, cyclosporine A; ATN, acute tubular necrosis; HLA, human leukocyte antigen.
a Mean values  SD, ratios or medians are shown
b Loss of kidney transplant function and dialysis became necessary in 5 of 15 patients within one year
c Loss of kidney transplant function and dialysis became necessary in 4 of 15 patients within one year; one patient died
Control patients received no immunosuppressive drugs. The demographic data of the organ donors and recipi-
ents of 10 kidneys, whose biopsies were investigated byIn patients treated with a CsA-based immunosuppres-
sive therapy, CsA blood trough levels were kept in a immunohistochemistry before and after transplantation,
are summarized in Table 2.range of 100 to 300 ng/mL. In addition to CsA (average
dosage 3 to 6 mg/kg body wt/day), prednisone (de-
Immunohistochemical staining for P-gppending on the time after transplantation between 5 and
50 mg/day) was given with or without azathioprine (1.5 to One-micrometer thick sections of 4% paraformalde-
hyde-fixed, paraffin-embedded tissues were put onto2.5 mg/kg body wt/day) or MMF (1 to 2 g/day). In the
group with a CsA-free therapy regimen, the immunosup- glass slides and dried at 37C overnight. Specimens were
deparaffinized in xylene, rehydrated in ethanol and dis-pressive therapy consisted of either MMF (1 to 2 g/day)
or azathioprine (1.5 to 2.5 mg/kg body wt/day) in combi- tilled water and washed in phosphate-buffered saline
(PBS). Endogenous peroxidase activity was quenchednation with steroids. Induction therapy with antilympho-
cytic antibodies (ATG or OKT3) was only administered for 15 minutes with 0.3% H2O2 in methanol (vol/vol) at
room temperature (RT) followed by washing in PBS.in 2 out of 30 patients with cellular rejection, in 1 out
of 10 patients with vascular rejection, and in 3 out of 10 Specimens used for staining with mAbs UIC2 were mi-
crowave heated for 14 minutes in a buffer solution con-patients with ATN. In all other groups, antibody treat-
ment had not been used at least one year before biopsy. taining 1.8 mmol/L citric acid and 8.2 mmol/L sodium
citrate, followed by another washing in PBS [24]. ToSteroid-sensitive rejection episodes had occurred in 4 out
of 19 patients with acute or chronic CsA nephrotoxicity, reduce nonspecific binding, all slides were incubated for
30 minutes with pooled, heat-inactivated antinuclear anti-shortly before biopsy (6 months).
The patients received no other drugs known to induce body (ANA), and antineutrophil cytoplasmic antibody
(ANCA)-negative human serum diluted 1:5 in PBS. ThenP-gp. Although antihypertensive medication was neces-
sary in most cases, the calcium antagonists verapamil primary mouse mAbs UIC2 (1:50) or MRK16 (1:100)
[25, 26], diluted in PBS or mouse IgG as a negativeand diltiazem, which are known to be inducers and sub-
strates of P-gp [22, 23], were avoided because of possible control, were applied for one hour at RT. After washing
in PBS, slides were incubated for 30 minutes with a HRP-drug interactions with CsA.
The main demographics of the transplant recipients un- conjugated secondary rabbit anti-mouse antibody at a
dilution of 1:50. After washing in PBS, a HRP (POD)-der CsA treatment, CsA-free immunosuppression (MMF,
azathioprine), and organ donors are summarized in Table conjugated goat anti-rabbit antibody was applied for 30
minutes at RT at a dilution of 1:100. After another wash-1. Moreover, time after transplantation and serum creati-
nine levels at the time of biopsy and one year after biopsy ing in PBS, slides were incubated with the chromogenic
substrate AEC for three minutes (MRK16) or five min-are documented. There were no statistically significant
differences between donors’ age, patients’ age, gender, utes (UIC2) at RT to obtain positive (red) tissue staining.
The reaction was stopped by washing in PBS followedpreformed panel reactive antibodies, or numbers of hu-
man leukocyte antigen (HLA) mismatches in each group. by nuclear counterstaining with hematoxylin. Slides were
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Table 2. Demographic data of organ donors (zero biopsies) and recipients
Serum creatinine Preformed HLA Number of HLA Median time after
Age years Male:female mg/dL antibodies (5%) mismatches transplantation days
Organ donors (N10) 43.813.6 5:5 0.930.26 — — —
Organ recipients (N10) 40.414.3 7:3 1.740.27 0/10 2.81.3 14
HLA is human leukocyte antigen.
Mean values  SD, ratios or medians are shown.
Table 3. Semiquantitative evaluation after immunostaining of normal human kidney or renal allograft biopsies with mAb UIC-2
Acute Acute Acute Chronic Acute/chronic
Normal tubular CsA cellular vascular allograft allograft
Diagnosis kidneys necrosis nephrotoxicity rejection rejection nephropathy nephropathy
CsA treatment No Yes Yes Yes Yes Yes No
N 13 10 19 30 10 10 15
Arterial endothelia 2/13 (16%) 6/10a (60%) 4/19 (21%) 10/30 (33%) 5/10a (50%) 6/10a (60%) 3/15 (20%)
Proximal tubules (BB
and/or intracellular) 1/13 (8%) 7/10a (70%) 4/19 (21%) 11/30 (37%) 3/10 (30%) 7/10a (70%) 4/15 (27%)
BC (epithelial cells) 5/13 (39%) 10/10a (100%) 10/19 (53%) 21/30a (70%) 7/10 (70%) 6/10 (60%) 3/15 (20%)
Lymphocytic
infiltrates 0/13 (0%) 0/10 (0%) 0/19 (0%) 26/30a (87%) 10/10a (100%) 5/10a (50%) 2/15 (13%)
Abbreviations are: BB, brush border; BC, Bowman’s capsule; CsA, cyclosporine A.
Ratios (percentages) of moderately (2) and strongly (3) positive staining were considered for statistical analysis.
a P  0.05 compared to normal human kidneys using Mantel-Haenszel test for unpaired samples [27]
Table 4. Semiquantitative evaluation after immunostaining of zero biopsies and of the same kidneys after CsA treatment with mAb UIC-2
Arterial Proximal tubules BC Lymphocytic
N endothelia (BB and/or intracellular) (epithelial cells) infiltrates
Zero biopsies 10 2/10 (20%) 4/10 (40%) 3/10 (30%) 0/10 (0%)
Biopsies after CsA treatment 10 9/10a (90%) 7/10a (70%) 10/10a (100%) 6/10a (60%)
CsA is cyclosporine A.
Ratios (percentages) of moderately (2) and strongly (3) positive staining were considered for statistical analysis
a P  0.05 compared to normal human kidneys using Mantel-Haenszel test for unpaired samples [27]
mounted on glycerol gelatin and viewed in a noninverted only moderately and strongly positive structures (2 and
3) were considered.microscope using objectives of 	10, 	20, and 	40. Im-
ages were taken with a Zeiss camera using an Agfach-
Isolation and culture of peripheral mononuclear cellsrome RSX50 film.
Peripheral mononuclear cells (PBMCs) were isolatedHematoxylin and eosin (HE) staining was performed
from heparinized blood of healthy donors by density gra-as routine staining for the detection of infiltrating lym-
dient centrifugation using Ficoll Histopaque (Biologischephocytes, as described earlier [21].
Analysesysteme GmbH, Lich, Germany). Contaminating
red blood cells were lyzed, and PBMCs were washed andEvaluation of sections
counted. Cells were seeded at a concentration of 5 	 106Intensity and distribution of immunohistochemical
cells per flask in 25 mL RPMI-1640 medium supplementedstaining for P-gp were compared in biopsies of normal
with 10% fetal calf serum, 100 U/mL penicillin G, 100
human kidneys and renal allografts. The different renal

g/mL streptomycin sulfate, 10 mmol/L HEPES buffer
structures, arterial vessels, tubules, brush borders of PTs, (pH 7.4 with NaOH), and 10 mmol/L glutamine. Then,
epithelial cells of Bowman’s capsule (BC), as well as they were incubated for three days in a 95% O2/5% CO2
infiltrating leukocytes were evaluated separately and atmosphere with either 0.1% (vol/vol) DMSO used as a
scored as follows: 0  no staining; 1  25%, but control, therapeutically relevant concentrations of CsA
50% of cells were positively stained and/or staining (125 to 3000 ng/mL), or concentrations of TNF- (1 to 25
intensity was weak; 2  51 to 75% of cells were posi- ng/mL) that have been detected in human disease [27].
tively stained and/or staining intensity was moderate;
SDS-PAGE and immunoblottingand 3more than 75% of cells were positively stained
and/or staining intensity was strong. For statistical analy- Cells were solubilized by addition of threefold concen-
trated sodium dodecyl sulfate (SDS) sample buffer andsis of immunohistochemical staining (Tables 3 and 4),
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sonicated for 30 seconds on ice. Following centrifugation, of ATN increases with CsA induction therapy [31]. There-
fore, P-gp expression was examined in 10 cases of histo-proteins (50 
g/lane) were separated by SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) on 7.5% acryl- pathologically proven ATN under CsA treatment. P-gp
expression was significantly higher (P 0.05) in the brushamide Laemmli minigels and transferred to PVDF mem-
branes. Blots were blocked with 3% nonfat dry milk in border of PTs and in epithelial cells of BC. Brush borders
of PTs revealed a moderate to strong staining in cases,TBS  0.05% Tween 20 for eight hours and incubated
with a mAb to P-gp (C219, 5
g/mL) overnight. Following in which the cellular structures were not destroyed by
ATN-associated damages (Fig. 2, arrow). Increased ex-incubation with a HRP-conjugated secondary antibody
(1:6000 dilution) for one hour, blots were developed in pression of the MDR gene product was detected in the
endothelial cell lining of small arteries and arterioles,enhanced chemiluminescence (ECL) reagents and visu-
alized on x-ray films. Processing for documentation and which differed significantly from controls (P  0.05; Fig.
2, arrowhead), whereas glomerular and peritubular capil-quantitative analysis of x-ray film signals was performed
essentially as described earlier [20]. laries remained negative. Rare leukocytic infiltrates did
not stain positively for P-gp. Biopsies of patients (3 out of
Statistical analysis 10) treated with antilymphocytic antibody preparations
were not different (data not shown).Statistical analysis of immunohistochemical data was
carried out with the BIAS (biometrical analysis of ran-
Expression of P-gp in transplant kidneys withdom samples) program using the Mantel-Haenszel test
CsA-induced acute or chronic nephrotoxicityfor unpaired [28] and McNemar test for paired samples
[29]. For quantitative analysis of immunoblot experi- Although the short-term graft survival rate has im-
proved since introduction of CsA as an immunosuppres-ments, unpaired Student t test was used. Results with
sant, the long-term survival rates of renal allografts arelevels of P  0.05 were considered significant.
not very different from those of the pre-CsA era [1].
The major side effects of CsA are acute or chronic neph-
RESULTS rotoxicity, which lead to a delayed graft function or late
Immunohistochemical staining of 13 normal kidney deterioration of graft function in association with charac-
biopsies and 94 allograft biopsies was performed to eval- teristic histopathological changes of the kidney such as
uate the effect of CsA treatment on P-gp expression and tubular vacuolization or media hyalinosis of arterioles
distribution in renal allografts with different histopatho- [11]. We studied 19 cases of histologically proven CsA
logical diagnoses. The results after immunostaining with nephrotoxicity for the distribution of P-gp in the renal
the mAb UIC2 are summarized in Table 3. Distribution biopsies. P-gp expression during acute (N 8) or chronic
of P-gp after immunostaining with the mAbs UIC2 or (N  11) CsA nephrotoxicity did not differ significantly
MRK16 was comparable. Furthermore, the time course from that of normal human kidneys (Table 3). A weak,
of P-gp expression was examined in 10 cadaveric donor nonpolarized expression of P-gp was detected in PTs of
organs in biopsies taken before implantation and after acute CsA-associated tubulotoxicity (Fig. 3 arrow). In
implantation in patients under CsA treatment (Table 4). contrast to renal biopsies of other CsA-treated patients,
those of patients with CsA nephrotoxicity showed less
Expression of P-gp in normal human kidneys expression of P-gp in the arterial endothelial cell lining
Figure 1 shows a representative biopsy of normal kid- (Table 3). Prior administration of steroid, pulses before
neys after immunostaining with mAb UIC2. P-gp was biopsy in 4 out of 19 patients did not affect P-gp expres-
found to be weakly expressed in the brush border of PTs sion (data not shown).
(Fig. 1, arrows), and quite unexpectedly, strong intracel-
Expression of P-gp in transplant kidneys with acutelular staining was observed in distal tubules. Moderate
cellular or vascular rejection under CsA treatmentto strong expression in the epithelial cells of BC was
detected in 5 out of 13 biopsies (Table 3). In most cases, Early acute rejection episodes have a major effect
endothelial cells of renal arteries and arterioles did not on allograft survival. Some allografts with delayed graft
express P-gp (Fig. 1, arrowhead). No P-gp was detectable function due to acute rejection do not regain function,
in glomerular and peritubular capillaries and in intersti- even with maximal antirejection therapy. Despite the
tial cells. fact that new potent immunosuppressive drugs have been
developed for the prophylaxis of acute renal allograft
Expression of P-gp in transplanted kidneys of patients rejection, acute and especially acute recurrent rejection
with ATN under CsA treatment episodes still remain a major problem leading to reduced
One major cause of delayed graft function in the early long-term allograft survival [5, 32]. We have examined
post-transplantation period with an impact on allograft P-gp distribution in 30 cases of acute cellular and 10 cases
of acute vascular rejection episodes after CsA treatment.survival is the development of ATN [30]. The incidence
Fig. 1. Expression of P-glycoprotein (P-gp) in normal human kidney
determined with monoclonal antibody (mAb) UIC-2. P-gp is weakly
expressed in the brush borders of proximal tubules (arrow) and strongly
in intracellular structures of distal tubules. No P-gp expression is de-
tected in endothelia of glomerular and peritubular capillaries or in
arterioles (arrowhead). Magnification 	400.
Fig. 4. Expression of P-glycoprotein (P-gp) in acute renal allograft rejec-
tion. Strong expression is shown in infiltrating mononuclear cells (aster-
isks), determined with mAbs MRK16 (A) or UIC2 (B). Increased P-gp
expression is also detected in endothelial cells of arteries (arrowhead; A)
as well as in brush borders of proximal tubules (arrow; B). Magnification
	400.
Fig. 2. Expression of P-glycoprotein (P-gp) in a renal allograft with
acute tubular necrosis under cyclosporine A (CsA) therapy. P-gp expres-
sion is increased in the brush border of proximal tubules (arrow) com-
pared with control kidneys. P-gp expression in endothelial cells of arter-
ies and arterioles is also detected (arrowheads). Magnification 	600.
Fig. 5. Expression of P-glycoprotein (P-gp) in a renal allograft at time
of implantation (zero biopsy; A) and under CsA-treatment (B). A homo-
geneous, nonpolarized staining pattern in tubules (arrow) is found in
a zero biopsy after cold ischemia (A), whereas arterial endothelia do
not express P-gp (arrowhead). Under CsA therapy (B), a redistribution
Fig. 3. Expression of P-glycoprotein (P-gp) in a renal allograft with to the brush borders of proximal tubules (arrow) and a de novo expres-
CsA-nephrotoxicity. A weak, homogeneous nonpolarized staining pat- sion in arterial endothelia (arrowhead) are detected in a subsequent
tern in proximal tubules is shown after immunostaining with mAb UIC-2 biopsy of the same kidney taken because of rejection. Immunohisto-
(arrow). Magnification 	600. chemical staining with mAb UIC-2. Magnification	600 (A),	800 (B).
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The most striking observation concerned infiltrating allograft tissue. Diagnoses included chronic allograft ne-
phropathy (N  10), acute allograft rejection (N  2),mononuclear cells that showed a strong P-gp expression
in both acute cellular and vascular rejection (Fig. 4, aster- and others (N  3). The biopsies did not show any
significant increase in P-gp expression in arterial endo-isks). Expression of P-gp in mononuclear cells increased
in intensity with the histopathologic and clinical severity thelia, PTs or epithelial cells of BC compared with nor-
mal kidneys. Moreover, only 2 out of the 15 biopsiesof rejection (Banff I and II vs. III) and thus appeared
to be strongest in cases of vascular rejection (Table 3). showed an increased expression of P-gp in infiltrating
lymphocytes (Table 3).Twenty-six of 30 patients with cellular rejection had a
moderate to strong P-gp expression, with a mean inten-
P-gp expression in zero biopsies of cadavericsity of 2.0 for the whole group, whereas all patients in
donor organs and of the same kidneys afterthe group with vascular rejection showed a moderate to
immunosuppressive therapy with CsAstrong P-gp expression with a mean intensity of 2.4.
Moreover, increased expression of P-gp occurred in arte- The intra-individual time course of P-gp expression
was investigated in 10 cadaveric organs before (zerorial endothelia in acute cellular and vascular rejection
(Fig. 4A, arrowhead); however, this increase was signifi- biopsy) and under CsA treatment. To study the effect
of renal ischemia on P-gp expression, zero biopsies,cant only in vascular rejection. In PTs, both intracellu-
larly and in brush borders (Fig. 4B arrow and Table 3), which were taken after cold perfusion of donor organs
with preservation solution, were also compared withP-gp expression was increased compared with controls,
but these changes did not reach significance. Epithelial those of normal control kidneys. Moreover, the intra-
individual changes of P-gp staining were also investi-cells of BC stained moderately to strongly positive for
P-gp in 70% for both forms of acute rejection. Distribu- gated in order to detect possible differences in CsA-
inducible P-gp expression among donors. Zero biopsiestion of P-gp after immunostaining with mAbs UIC2 or
MRK16, respectively, was comparable (Fig. 4). How- showed a weak, but nonpolarized distribution of P-gp in
PTs (Fig. 5A, arrow), which somehow differed from aever, a more distinct and stronger staining for P-gp was
obtained with mAb MRK16 in infiltrating mononuclear more apical staining found in the PTs of normal kidneys
(Fig. 1, arrow). Arterial endothelia stained positively incells, which were identified as lymphocytes with HE
staining by light microscopy. only 2 of 10 cases (Fig. 5A, arrowhead). Brush borders
of PTs as well as epithelial cells of BC showed a positive
Expression of P-gp in kidney transplants with chronic P-gp expression in 2 and 3 of 10 biopsies, respectively
allograft nephropathy and CsA treatment (Table 4). All in all, apart from a difference in the cellular
distribution of P-gp in PTs, P-gp expression in zero biop-Chronic allograft nephropathy is the most frequent rea-
son for renal transplant failure. It may be caused by im- sies was quite similar to that found in biopsies from
normal kidneys (Table 3).munologic as well as nonimmunological factors; for ex-
ample, repeated rejections, hyperlipidemia, or arterial In contrast to zero biopsies, P-gp expression increased
after CsA treatment in subsequent transplant biopsieshypertension [4]. We investigated 10 cases of histopatho-
logically proven chronic allograft nephropathy and immu- taken to diagnose the cause of graft dysfunction. P-gp
expression was up-regulated in PTs and was particularlynosuppressive treatment with CsA, but without showing
histopathological signs of chronic CsA-nephrotoxicity, increased in the brush borders of PTs (Fig. 5B, arrow)
and arterial endothelia (Fig. 5B, arrowhead) after CsAthat is, there was no CsA-associated arteriolopathy in
these patients. P-gp was significantly up-regulated in the treatment (Table 4) and, in the case of rejection as the
underlying diagnosis, also in mononuclear infiltratesarterial endothelial cell lining and PTs. Moreover, in-
creased expression of P-gp was also seen in epithelial (Fig. 5B). As an example, intra-individual differences of
endothelial P-gp expression in zero biopsies and trans-cells of BC. Infiltrating lymphocytes moderately to
strongly (2 to 3) expressed P-gp in 5 out of 10 patients plant biopsies during CsA treatment are summarized in
Figure 6.(Table 3), but low-grade (1) staining of lymphocytes
for P-gp was seen in all biopsies.
Expression of P-gp in human PBMCs incubated with
CsA or TNF-Expression of P-gp in kidney transplants with a
CsA-free immunosuppressive regimen P-glycoprotein expression in graft-infiltrating immune
cells was present in nearly all biopsies with acute rejec-To obtain further information about the possible
mechanisms underlying up-regulation of P-gp in kidney tion (Table 3). To substantiate the biopsy-derived in
vivo findings, the effects of therapeutic concentrationstransplant patients during acute and chronic allograft
rejection, allograft biopsies from patients taking an im- of CsA as well as of the inflammatory cytokine TNF-
on the expression of P-gp in human PBMCs in vitro weremunosuppressive regimen other than CsA were also in-
vestigated for P-gp expression and distribution in renal investigated.
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Fig. 6. Intra-individual changes of P-gp expression in arterial endothe-
lia of cadaveric kidney allografts on zero biopsies and subsequent biop-
sies under CsA treatment. Staining intensity of arterial endothelia re-
flecting P-gp expression is evaluated semiquantitatively, as described
in the Methods section. The figure compares biopsies from the same
cadaveric kidney allografts before implantation and during CsA treat-
ment. With the exception of one organ, all kidneys showed increased Fig. 8. P-glycoprotein expression in human PBMCs incubated with
P-gp expression in arterial endothelia after CsA-treatment, although increasing concentrations of TNF-. PBMCs were left untreated (co)
interindividual P-gp levels varied considerably. or were incubated for three days with different concentrations of TNF-
(1, 5, 10, or 25 ng/mL). Immunoblotting was carried out using the mAb
C219 (5 
g/mL; A). (B) Quantitative analysis of immunoblots was
performed exactly as described in Figure 7B. Means SD of five different
experiments are shown (*P  0.05, using unpaired Student t test).
The first lane of each blot shows constitutive expression
of P-gp in PBMC. Figure 7B provides a quantitative
analysis of immunoblots of three different experiments.
P-gp expression was quantitated by measuring the optical
density of immunoreactive bands with controls set to
100%. CsA treatment for three days increased P-gp ex-
pression, starting with a concentration of 125 ng/mL, and
was maximally increased to 942 298% of controls after
incubation with CsA at 3000 ng/mL (P  0.05; Fig. 7B).
Similarly, the cytokine TNF- that had been detected
in allograft rejection [33] increased P-gp levels up to a
maximum of 223  90% of controls after stimulation
with 25 ng/mL TNF- (P  0.05; Fig. 8).
DISCUSSIONFig. 7. P-glycoprotein expression in human peripheral blood mononu-
clear cells (PBMCs) incubated with increasing concentrations of CsA. To detect P-gp in allograft biopsies, we used two differ-
PBMCs are left untreated (co) or incubated for three days with thera-
ent mAbs that are directed against different extracellularpeutically relevant concentrations of CsA (125, 250, 500, 1500, or 3000
ng/mL). The immunoblot was probed with the mAb C219 (5 
g/mL; epitopes of P-gp [34, 35]. Both antibodies stained identi-
A). Immunoreactive protein bands detected by immunoblotting (A) cal renal structures in paraffin sections, but with slightly
were analyzed by densitometry. P-gp expression was determined as a
different intensities: MRK16 less intensely stained renalpercentage of the total amount of immunoreactive protein present in
control PBMCs. Means  SD of three different experiments are shown parenchymal cells than UIC2, but very strongly stained
(B; *P  0.05, using unpaired Student t test). the infiltrating lymphocytes (Fig. 5). Both antibodies
stained P-gp in paraffin sections very specifically and
distinctly. Therefore, both UIC2 and MRK16 may be
useful tools if P-gp staining finds a place in the routineThe presence of P-gp was ascertained by immunoblot
histopathological diagnostics of transplant biopsies.analysis with the P-gp specific mAb C219 (5 
g/mL). Fig-
Biopsies with ATN under CsA treatment showed anure 7A shows a representative immunoblot of lysates from
increased P-gp expression in brush borders of PTs butPBMCs that had been incubated with therapeutically rele-
vant doses of CsA (125 to 3000 ng/mL) for three days. also intracellularly (Fig. 2 and Table 3). What is the
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nature of the intracellular structures associated with P-gp ture studies to investigate the role of other CsA-detoxify-
immunostaining? Recent studies indicate that functional ing systems in kidney allograft biopsies, such as the me-
P-gp may also be expressed in intracellular organelles tabolizing cytochrome P450 enzyme system [12] or the
of PT cells [36] and various nonrenal tissues [37–39]. It multispecific organic anion transporter (MRP2) [13].
also seems reasonable to assume that cells overexpress- Our study also examined P-gp expression in graft-
ing a plasma membrane transporter will shuttle this infiltrating mononuclear cells of CsA-treated renal trans-
transporter to the cell surface via intracellular membrane plant recipients rejecting their graft. We found that acute
vesicles. This suggests that CsA may induce its own de- and chronic rejections were associated with high levels
toxification system in renal parenchymal cells in vivo of P-gp expression of graft-infiltrating mononuclear cells
by up-regulating the ATP-binding cassette transporter,
in CsA-treated patients (Table 3 and Fig. 4). In addition,P-gp. This hypothesis is supported by the observation
in vitro incubation with therapeutic concentrations ofthat in kidney transplant patients with acute or chronic
CsA increased P-gp expression in human PBMCs (Fig. 7).rejection who are on a CsA-free immunosuppressive reg-
The level of P-gp expression correlated with the severityimen, no measurable P-gp up-regulation in PTs, epithe-
of rejection showing highest levels of expression in vascu-lial cells of the BC, and arterial endothelia was observed,
lar rejection (Table 3). CsA is a substrate of P-gp thatas opposed to the same groups of patients on CsA treat-
extrudes the drug out of cells [14]. Up-regulation of P-gpment (Table 3). While there are precedents for this cellu-
in the membrane of mononuclear cells could decreaselar adaptation to drug-induced toxicity in studies with
cytosolic CsA concentrations in graft-infiltrating lym-cell lines [22], including our own previous in vitro studies
with PT and arterial endothelial cell lines [20], our cur- phocytes, resulting in inadequate immunosuppression
rent study is the first detailed analysis in transplant pa- despite immunosuppressive concentrations of CsA in the
tients, to our knowledge. extracellular fluid. This hypothesis gains support from
As shown in Table 3, CsA-treated patients with ATN, studies correlating P-gp expression in mononuclear cells
acute allograft rejection, or chronic allograft nephropa- of peripheral blood with the incidence of acute or chronic
thy expressed P-gp in nephron structures that are pre- rejection in CsA-treated heart [44] or renal transplant
dominantly affected by CsA-induced nephrotoxicity, patients [45]. However, this observation remains contro-
namely PTs and vascular endothelial cells [11, 40, 41]. versial since one group found no correlation between P-gp
Therefore, at first glance it appears paradoxical that allo-
expression in PBMCs during acute renal allograft rejec-graft biopsies with CsA nephrotoxicity showed only a
tion [46]. Interestingly, though the cytokine TNF- in-slight, nonsignificant increase of P-gp expression in PTs
creased P-gp expression in PBMC in vitro, in patientsor epithelial cells of the BC, as well as a lack of P-gp
having chronic transplant failure of their graft under ainduction in endothelial cell linings of small arteries and
CsA-free therapeutic regimen, only two out of 15 biop-arterioles compared with controls (Table 3). One could
sies showed a significant up-regulation of P-gp in infil-argue that CsA induces severe cell damage and thereby
trating lymphocytes. This finding is different from theprevents P-gp up-regulation in these particular cases of
group with chronic allograft nephropathy under CsAnephrotoxicity. However, severely damaged tubules,
treatment. This suggests that the contribution of CsA tosuch as found in ATN, were able to up-regulate P-gp
after CsA treatment. Moreover, patients with acute vas- P-gp up-regulation is the predominant factor (Figs. 7 and
cular or chronic allograft rejection who displayed a simi- 8). It has been suggested that P-gp is also involved in
lar degree of long-term renal dysfunction (Table 1) also the transport of cytokines, for example, IL-2, across the
showed increased P-gp expression (Table 3). Therefore, cell membrane in lymphocytes [17, 47]. Up-regulation
it appears more likely that CsA nephrotoxicity is the of P-gp by CsA in graft-infiltrating mononuclear cells
consequence of an inadequate up-regulation or of a con- could therefore be associated with a higher local and/or
stitutively low expression of P-gp in individual kidneys, systemic cytokine secretion and induce or enhance rejec-
which may result in accumulation of CsA or other exoge- tion episodes by increasing the proliferation of activated
nous or endogenous toxic compounds and in the long
lymphocytes.
term lead to CsA-induced nephrotoxicity. This hypothe-
We also provide the first data, to our knowledge, de-sis is in accordance with data by del Moral et al, who
scribing intra-individual time courses of P-gp expressionshowed an inverse correlation of P-gp expression and
in human renal allografts before and during CsA treat-CsA nephrotoxicity in a rat model of renal CsA-toxicity,
ment. It is known that an extended cold ischemia time insuggesting a functional role of P-gp as a detoxicant in
combination with severe tissue damage and reperfusionrenal cells [42]. The results also agree with the hypothesis
injury lead to a reduced short- and long-term allograftof Bennett et al that accumulation of toxic compounds
survival [30]. Ischemia may result in loss of PT cell polarity.as a consequence of insufficient clearance by P-gp causes
CsA nephrotoxicity [43]. It would be interesting for fu- For instance, Kwon et al have demonstrated that ischemia
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of renal allografts of cadaveric organs causes increased APPENDIX
cytoplasmic redistribution of basolateral Na/K-ATPase Abbreviations used in this article are: ABC, ATP-binding cassette;
AEC, 3-amino-9-ethyl-carbazol; ANA, antinuclear antibody; ANCA,in PTs [48]. Not unexpectedly, P-gp immunostaining in
antineutrophil cytoplasmic antibody; ATN, acute tubular necrosis; BB,10 donor organ biopsies taken after ischemia showed
brush border; BC, Bowman’s capsule; CsA, cyclosporine A; DMSO,
an increased intracellular distribution in PTs (Fig. 5A) dimethyl sulfoxide; HE, hematoxylin and eosin; HLA, human leuko-
cyte antigen; HRP, horseradish peroxidase; IL-2, interleukin-2; mAb,compared with the same donor kidneys re-examined after
monoclonal antibody; MDR, multidrug resistance; MMF, mycopheno-transplantation (median value 14 days), which showed a late mofetil; NF-AT, nuclear factor of activated T cells; PBMCs, periph-
predominant expression of P-gp in the brush border (Fig. eral blood mononuclear cells; P-gp, P-glycoprotein; POD, peroxidase;
PT, proximal tubule; PVDF, polyvinyldene difluoride; RT, room tem-5B). Therefore, the intracellular redistribution of P-gp
perature; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel elec-
in ischemic kidneys could result in an inefficient extru- trophoresis; TNF-, tumor necrosis factor-.
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